Apogee Therapeutics Inc
APGE
Company Profile
Business description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
Contact
221 Crescent Street
Building 17, Suite 102b
WalthamMA02453
USAT: +1 650 394-5230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
91
Stocks News & Analysis
stocks
Signs of a turnaround for undervalued ASX share
Market likes the payoff from early efforts at reining in costs.
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
Ashley Owen explores why investors' insatiable thirst for higher yields leads to unnecessarily complicating their portfolio.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,825.10 | 20.90 | 0.24% |
CAC 40 | 8,178.54 | 14.43 | 0.18% |
DAX 40 | 22,513.42 | 98.60 | -0.44% |
Dow JONES (US) | 44,579.30 | 132.13 | -0.30% |
FTSE 100 | 8,732.46 | 32.26 | -0.37% |
HKSE | 22,620.33 | 805.96 | 3.69% |
NASDAQ | 19,944.56 | 1.08 | -0.01% |
Nikkei 225 | 39,149.43 | 312.04 | -0.79% |
NZX 50 Index | 12,989.18 | 83.20 | 0.64% |
S&P 500 | 6,109.29 | 5.78 | -0.09% |
S&P/ASX 200 | 8,555.80 | 15.80 | 0.19% |
SSE Composite Index | 3,346.72 | 14.24 | 0.43% |